Pfizer To Base COVID-19 Vaccine Price On Existing Vaccine Prices

By John Wilkerson / June 26, 2020 at 6:36 PM
Pfizer plans to base the price of its coronavirus vaccine candidate on prices of existing vaccines and anticipates offering bulk discounts, Pfizer Chairman and CEO Albert Bourla said Friday (June 26), but he expects the company to make a profit from the vaccine. The company has separate supply networks for the United States and Europe, and Bourla increased the number of doses he thinks the company could make this year and next. Basing the price of a coronavirus vaccine on...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.